Literature DB >> 9683033

Neutrophil adhesion to histamine stimulated cultured endothelial cells is primarily mediated via activation of phospholipase C and nitric oxide synthase isozymes.

U Schaefer1, A Schneider, D Rixen, E Neugebauer.   

Abstract

OBJECTIVE AND
DESIGN: In order to understand the underlying mechanism of histamine stimulated inflammatory responses, histamine receptor subtypes and signal transduction pathways by which histamine mediates the stimulation of neutrophil adhesion to endothelial cells has been studied in vitro. MATERIAL: Human neutrophils and human umbilical vein endothelial cells. TREATMENT: Confluent human endothelial cell layer were incubated with histamine (1 mM), H1, H2 or H3 receptor agonists: fluorophenylhistamine (10 microM), amthamine (10 microm), methylhistamine (10 microM), respectively. Ten minutes prior to histamine (1 mM) stimulation H1, H2 or H3 receptor antagonists (dimethindene, 100 microM; famotidine, 1OO microM, thioperamid 100 microM, respectively) were added. Histamine stimulated signal transduction pathways were inhibited by adding phospholipase C inhibitor 2-nitro-4-carboxyphenyl N,N-diphenylcarbamat (200 microM), adenylate cyclase inhibitor 9-(2 tetrahydrofuryl)adenine (80 microM), nitric oxide synthase isozymes inhibitor S-ethylisothiourea (1 microM) or guanylate cyclase inhibitor (LY 83583; 10 microM). Neutrophil adhesion was monitored at 30, 60, 90, 120, 150, 180 and 210 min.
METHODS: Neutrophil adhesion to endothelial cells was quantified by analysing alkaline phosphatase activity.
RESULTS: Histamine stimulation of endothelial cells resulted in a biphasic time and concentration dependent pattern of neutrophil adhesion. This pattern of neutrophil adhesion was mimicked by stimulation of endothelial cells with H1 or H2 agonists. Stimulation of endothelial cells with an H3 agonist had no effect on neutrophil binding. Inhibition of phospholipase C (PLC), nitric oxide synthase isozymes (NOS) or guanylate cyclase (GC) resulted in a significant decrease of neutrophil binding to histamine or agonist stimulated endothelial cells. An increase of neutrophil binding to unstimulated or to agonist stimulated endothelial cells was observed during inhibition of adenylate cyclase.
CONCLUSIONS: Our results suggest that histamine stimulated neutrophil adhesion is due to H1 and H2 receptor mediated activation of PLC, NOS and GC. Increase of cAMP concentration seems to mediate an inhibitory effect on PMN adhesion to endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9683033     DOI: 10.1007/s000110050327

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  5 in total

1.  Melatonin inhibits nitric oxide production by microvascular endothelial cells in vivo and in vitro.

Authors:  C L M Silva; E K Tamura; S M D Macedo; E Cecon; L Bueno-Alves; S H P Farsky; Z S Ferreira; R P Markus
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

2.  The role of endogenous histamine on the pathogenesis of the lipopolysaccharide (LPS)-induced, acute lung injury: a pilot study.

Authors:  Tae-Hyung Kim; Ho Joo Yoon; Chae Man Lim; Eun-Kyung Kim; Mi Jung Kim; Younsuck Koh
Journal:  Inflammation       Date:  2005-04       Impact factor: 4.092

3.  The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.

Authors:  Kevin Wilhelmsen; Samira Khakpour; Alphonso Tran; Kayla Sheehan; Mark Schumacher; Fengyun Xu; Judith Hellman
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

4.  Effects of histamine on cultured interstitial cells of cajal in murine small intestine.

Authors:  Byung Joo Kim; Young Kyu Kwon; Euiyong Kim; Insuk So
Journal:  Korean J Physiol Pharmacol       Date:  2013-04-10       Impact factor: 2.016

5.  The new cardioprotector Monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro.

Authors:  M A I Abou El Hassan; H M W Verheul; A S Jorna; C Schalkwijk; J van Bezu; W J F van der Vijgh; A Bast
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.